Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS

Secondary Progressive Multiple Sclerosis (SPMS) Clinical Trial

Official title:
A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and Efficacy of an Intrathecal Administration of SCM-010 in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Status Withdrawn

Clinical Trial Summary

Prospective, single center, open label, phase I/IIa escalating dose study. To evaluate the safety and efficacy of escalating doses of SCM-010 in subjects with SPMS.

Clinical Trial Description

Twelve (12) SPMS subjects will be enrolled in this study in two dose cohorts. Each subject will receive SCM- 010 by intrathecal (IT) administration at baseline and will be followed up for 24 weeks for efficacy and 48 weeks for safety. ;

Study Design

Related Conditions & MeSH terms

Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Neoplasm Metastasis
Sclerosis
Secondary Progressive Multiple Sclerosis (SPMS)

Clinical Trial Details

NCT number	NCT03696485
Study type	Interventional
Source	Stem Cell Medicine Ltd.
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	February 1, 2024
Completion date	February 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04593927` - Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
Active, not recruiting	`NCT03387670` - Multiple Sclerosis-Simvastatin Trial 2	Phase 3
Completed	`NCT01235455` - Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors	N/A